Account
Surgical instruments maker Covidien PLC (COV), which posted disappointing quarterly revenue growth Friday, said tight budgets and shaky economies are causing potential patients in the U.S. and Europe to continue to delay medical treatment."We saw very little change in the market environment over the last several months, with no rebound in the U.S. in procedures of interest to us," said Jose Almeida in a conference call with analysts. "In Western Europe, austerity programs and the economic slowdown continue to pressure all of med-tech, with particular weakness in Spain and Italy."Covidien makes surgical products used in gastrointestinal, urology and general procedures.The medical-device and pharmaceutical company's fiscal second-quarter sales grew 5.3% to $3.1 billion, but were just shy of analysts' expectations of $3.12 billion. While the miss wasn't particularly big, it was the first time Covidien had disappointed on the top line since July of last year, according to Thomson Reuters."...
Edwards Lifesciences (EW) said a new version of its nonsurgical heart valve met its primary study goal in a late-stage trial, and that it would seek U.S. regulatory ...
Medtronic Inc. (MDT) said its medical device for treating high blood pressure continued to benefit patients after two years, providing more data to support the adopt...
Edwards Lifesciences Corp. (EW) said that a new version of its nonsurgical heart valve met its primary study goal in a late-stage trial, and that it would seek U.S. ...
St. Jude Medical (NYSE:STJ) agreed to raise its dividend by 9% on Monday to 25 cents a share, payable on April 30 to shareholders of record on March 29.The St. Paul,...
EnteroMedics Inc. (ETRM) said its electric shock device for weight-loss failed to meet its key goal in a clinical trial, but that it would nonetheless forge ahead wi...
St. Jude Medical Inc. (STJ) plans to acquire Nanostim Inc., a closely held maker of wireless pacemakers, St. Jude Chief Executive Dan Starks said Friday at his compa...
St. Jude Medical Inc.'s (STJ) earnings fell 4% in the fourth quarter as sales in its core heart-rhythm management business continued to decline as a result of increa...
St. Jude Medical Inc.'s (STJ) earnings fell 4% in the fourth quarter as sales in its core heart-rhythm management business continued to decline as a result of increa...
St. Jude Medical (NYSE:STJ) reported a decline in fourth-quarter sales and earnings on Wednesday but was upbeat on the current fiscal year.The St. Paul, Minn.-based ...
Earnings HQ: FBN’s Diane Macedo breaks down STJ ’s fourth-quarter earnings report.
St. Jude Medical Inc.'s (STJ) fourth-quarter earnings fell 4% amid an increase in restructuring charges and other items, while the medical-device maker's revenue als...
St. Jude Medical Inc. said Wednesday its fourth-quarter profit dipped to $120 million, or 39 cents a share, from $125 million, or 39 cents a share, in the year-ago p...
The spike late last year in doctor and hospital visits apparently lasted as long as the flu.After years of decelerating health-care usage--linked to economic problem...
As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fe...
St. Jude Medical Inc.'s (STJ) first-quarter earnings rose 5.2% as lower costs offset weaker sales, while the medical-device maker's core heart-rhythm-management busi...
St. Jude Medical Inc.'s (STJ) first-quarter earnings rose 5.2% as lower costs offset weaker sales while the medical-device maker's core heart-rhythm management busin...
Medical device maker St. Jude Medical Inc said on Wednesday its quarterly earnings rose as expenses fell.First-quarter net earnings were $222 million, or 78 cents pe...
The march to make open-heart surgery a thing of the past continues.Edwards Lifesciences Inc. (EW) said its Sapien nonsurgical heart valve for elderly patients showed...
Mending a young person's broken heart may make for a good love story, but can it prevent strokes?That's a question the U.S. Food and Drug Administration is expected ...
